<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">1755</journal-id><journal-id journal-id-type="pmc-domain">frontonco</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10036360</article-id><article-id pub-id-type="pmcid-ver">PMC10036360.1</article-id><article-id pub-id-type="pmcaid">10036360</article-id><article-id pub-id-type="pmcaiid">10036360</article-id><article-id pub-id-type="pmid">36969023</article-id><article-id pub-id-type="doi">10.3389/fonc.2023.1138304</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Oncology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Moderately hypo-fractionated radiotherapy combined with S-1 in inoperable locally advanced esophageal squamous cell carcinoma: A prospective, single-arm phase II study (GASTO-1045)</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="R">Rui</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Luo</surname><given-names initials="G">Guangyu</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="S">Suping</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1444114"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="Y">Yingjia</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Luo</surname><given-names initials="Q">Qiaoting</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="D">Daquan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1900715"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="N">Naibin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="F">Fangjie</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1884857"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="J">Jinyu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ye</surname><given-names initials="W">Wenfeng</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Qiu</surname><given-names initials="B">Bo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Liu</surname><given-names initials="H">Hui</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1853554"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Radiation Oncology, Sun Yat-sen University Cancer Center</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>State Key Laboratory of Oncology in South China</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Lung Cancer Institute of Sun Yat-sen University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Guangdong Association Study of Thoracic Oncology</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><aff id="aff6">
<sup>6</sup>
<institution>Department of Endoscopy and Laser, Sun Yat-sen University Cancer Center</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><aff id="aff7">
<sup>7</sup>
<institution>Department of Nutrition, Sun Yat-sen University Cancer Center</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Adam Yongxin Ye, Boston Children&#8217;s Hospital and Harvard Medical School, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: David Zhan, Johns Hopkins Medicine and Johns Hopkins University, United States; Ran Xu, Dana&#8211;Farber Cancer Institute, United States; Jianli Zhang, Quanterix Corporation, United States</p></fn><corresp id="fn001">*Correspondence: Hui Liu, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:liuhuisysucc@126.com">liuhuisysucc@126.com</email>; Bo Qiu, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:qiubo@sysucc.org.cn">qiubo@sysucc.org.cn</email></corresp><fn fn-type="equal" id="fn003"><p>&#8224;These authors have contributed equally to this work and share first authorship</p></fn><fn fn-type="other" id="fn002"><p>This article was submitted to Gastrointestinal Cancers: Gastric and Esophageal Cancers, a section of the journal Frontiers in Oncology</p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>13</volume><issue-id pub-id-type="pmc-issue-id">427504</issue-id><elocation-id>1138304</elocation-id><history><date date-type="received"><day>05</day><month>1</month><year>2023</year></date><date date-type="accepted"><day>27</day><month>2</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>25</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-03-27 17:10:12.990"><day>27</day><month>03</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Zhou, Luo, Guo, Wu, Luo, Wang, Chen, Liu, Guo, Ye, Qiu and Liu</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Zhou, Luo, Guo, Wu, Luo, Wang, Chen, Liu, Guo, Ye, Qiu and Liu</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fonc-13-1138304.pdf"/><abstract><sec><title>Purpose</title><p>We launched this prospective phase II single-arm trial on the combination of moderately hypo-fractionated radiotherapy and S-1, to explore the safety and efficacy of the new potent regimen in inoperable locally advanced esophageal squamous carcinoma (LA-ESCC) patients.</p></sec><sec><title>Methods</title><p>Patients with unresectable stage II-IVB LA-ESCC (UICC 2002, IVB only with metastatic celiac or supraclavicular lymph nodes) were included. Moderately hypofractionated radiotherapy (60Gy in 24 fractions) concurrent with S-1 was delivered. Meanwhile, gastrostomy tube placement by percutaneous endoscopic gastrostomy (PEG) was performed to provide nutritional support. Nutritional supplements were prescribed to meet requirements. The study outcomes included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), locoregional progression-free survival (LRPFS), distant metastasis-free survival (DMFS), failure pattern, toxicities, nutritional status and treatment compliance. Endoscopy was routinely performed during post-treatment follow-up.</p></sec><sec><title>Results</title><p>Fifty-eight patients were included with a median follow-up of 24.4 months. The median age was 63 years (range 49-83 years) and 42 patients (72.4%) had stage III or IV diseases. The ORR was 91.3% and the CR rate was 60.3%. The estimated 2-year PFS rate and 2-year OS rate was 44.2% (95% confidence interval (CI), 31.3-57.1%) and 71.4% (95% CI, 59.4-83.4%), respectively. Radiation-induced esophagitis was the most common non-hematologic toxicity and 5 patients (8.6%) developed grade&#8805;3 esophagitis. While, with PEG nutrition support, the nutrition-related indicators presented a clear trend toward a gradual improvement. Treatment-related death was not observed.</p></sec><sec><title>Conclusions</title><p>The moderately hypo-fractionated radiotherapy combined with S-1 showed promising loco-regional disease control and survival benefit in inoperable LA-ESCC patients. Meanwhile, favorable nutritional status and low incidence of severe radiation-induced esophagitis were observed with PEG nutritional support. Moreover, endoscopy examination contributed to the early detection of recurrent esophageal lesions and timely salvage treatment. The efficacy and toxicity of the combined regimen deserved further evaluation.</p></sec><sec><title>Trial registration</title><p>Clinicaltrials.gov, identifier <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03660449">NCT03660449</ext-link>.</p></sec></abstract><kwd-group><kwd>locally advanced esophageal squamous cell carcinoma</kwd><kwd>moderately hypo-fractionated radiotherapy</kwd><kwd>S-1</kwd><kwd>percutaneous endoscopic gastrostomy</kwd><kwd>concurrent chemoradiotherapy</kwd></kwd-group><counts><fig-count count="5"/><table-count count="2"/><equation-count count="0"/><ref-count count="39"/><page-count count="11"/><word-count count="4900"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Based on the results of a series of Radiation Therapy Oncology Group (RTOG) studies, concurrent chemoradiotherapy (CCRT) had been considered as the standard therapeutic strategy for inoperable locally advanced esophageal squamous cell carcinoma (LA-ESCC) patients (<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B3" ref-type="bibr">3</xref>). However, approximately 45-55% of LA-ESCC patients developed disease recurrences after definitive CCRT with locoregional relapse as the predominant treatment failure pattern (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). To enhance the local control rate, some studies attempted to increase the fraction dose or total radiation dose to gross tumors. Nevertheless, the results of the landmark RTOG9405 trial showed that total dose escalation with conventional fraction failed to improve locoregional control (<xref rid="B1" ref-type="bibr">1</xref>). Another RTOG9012 trial found that escalating the radiation dose to 64.8 Gy did not confer a benefit compared with standard doses and may have contributed to a higher incidence of treatment-related severe toxicities (<xref rid="B4" ref-type="bibr">4</xref>). Recently, the ARTDECO study also approved that the total radiation dose escalation from 50.4 Gy to 61.6 Gy for esophageal carcinoma did not result in an improvement in local tumor control or survival (<xref rid="B5" ref-type="bibr">5</xref>). For that reason, fraction dose modification may be an option instead of total dose escalation. A trial conducted by Song demonstrated that moderately hypofractionated radiation could improve the local control rate with tolerable toxicities in inoperable LA-ESCC patients (<xref rid="B6" ref-type="bibr">6</xref>), which implied that moderately hypofractionated radiotherapy might offer therapeutic benefits with improved tumor control by increasing biologically effective doses (BED).</p><p>Although the concurrent dual-drug chemotherapeutic regimen was usually regarded as the preferred choice in previous studies (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>), it increased the incidence of serious adverse effects. In our previous phase I dose-escalation study of concurrent dual-drug chemotherapy, the results showed that the incidence of Grade 3-4 esophagitis and lymphopenia were 46.7% and 80%, respectively (<xref rid="B9" ref-type="bibr">9</xref>). Similarly, RTOG 8501 study reported that the rates of Grade 3-4 hematological toxicities and gastrointestinal reactions were 48% and 33%, which led to CCRT interruption and discontinuation (<xref rid="B3" ref-type="bibr">3</xref>). In a series of previous studies of the clinical outcomes of CCRT such as esophageal cancer, head and neck cancer, an interruption of treatment was found to be a negative factor in the local control (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). McCloskey et&#160;al. reported that radiotherapy interruption longer than 1 week was a significant predictor of worse local control after definitive CCRT (<xref rid="B12" ref-type="bibr">12</xref>). Therefore, potent new CCRT regimens with lower toxicity appeared to be crucial for inoperable LA-ESCC patients for the improvement of treatment compliance and outcomes.</p><p>S-1, an oral fluoropyrimidine anticancer drug, is composed of tegafur (prodrug of fluorouracil), gimeracil (dihydropyrimidine dehydrogenase inhibitor) and oteracil potassium (<xref rid="B13" ref-type="bibr">13</xref>). After oral intake, tegafur is gradually converted to 5-FU to exert anticancer effects by inhibiting DNA synthesis by competitive inhibition of thymidylate synthetase and incorporation into RNA and DNA. While the gimeracil component could inhibit the degradation of 5-FU to maintain high plasma concentrations. And the oteracil selectively inhibits the formation of 5-FU nucleotides in the gut, thereby reducing gastrointestinal side effects (<xref rid="B14" ref-type="bibr">14</xref>). In previous studies, S-1 as concurrent chemotherapy agents in combination with radiotherapy yielded satisfactory survival outcomes with tolerable toxicities in older patients with esophageal carcinoma (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). A recent phase III trial showed that there were no significant differences in the incidence of grade 3 or higher toxic effects between the S-1 CCRT and RT alone groups, except that grade 3 or higher leukopenia occurred in more patients in the CCRT group (9.5% <italic toggle="yes">vs</italic> 2.7%, P=0.01) (<xref rid="B17" ref-type="bibr">17</xref>). Notably, treatment-related deaths were observed in 3 patients (2.0%) in the CCRT group due to radiation-associated pneumonitis. In this context, intensive nutritional support is important for improving treatment tolerance and reducing toxicity in esophageal squamous cell carcinoma (ESCC) patients (<xref rid="B18" ref-type="bibr">18</xref>).</p><p>Therefore, we hypothesized that the moderately hypo-fractionated radiotherapy and concurrent S-1 would be able to reduce systemic toxicity and enhance loco-regional disease control; moreover, intensive percutaneous endoscopic gastrostomy (PEG) nutritional support and oral diet restriction during CCRT could be helpful for weight gain and reduce swallowing pain caused by radiation-induced esophagitis. We launched this prospective phase II clinical trial on the combination of moderately hypo-fractionated radiotherapy as well as concurrent S-1 and PEG nutritional support, to explore the safety and efficacy of the new potent regimen in inoperable ESCC patients.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and methods</title><sec id="s2_1"><title>Ethics</title><p>The study protocol was reviewed and approved by the institutional review board. Each participant signed an informed consent form before commencing the trial. And the study was conducted in accordance with the requirement of the Declaration of Helsinki.</p><p>The study protocol was registered at ClinicalTrials.gov (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03660449">NCT03660449</ext-link>) and was included in the <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Materials</bold>
</xref>.</p></sec><sec id="s2_2"><title>Inclusion and exclusion criteria</title><p>Study subjects were recruited between November 2017 and November 2019. All eligible patients met: 1) histologically confirmed ESCC; 2) II-IVB stages (IVB stage only with metastatic celiac or supraclavicular lymph nodes) based on the TNM staging system proposed by the International Union Against Cancer (UICC 2002) (<xref rid="B19" ref-type="bibr">19</xref>); 3) Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; 4) Charlson Comorbidity Index score &#8804; 4; 5) capability of oral medication despite esophageal obstruction; 6) adequate physical condition to tolerate PEG. The main exclusion criteria included: 1) contraindication for radiotherapy or chemotherapy; 2) prior malignancies, except for curable non-melanoma skin cancer or cervical carcinoma in situ; 3) distant metastasis, except for celiac or supraclavicular lymph nodes metastases.</p></sec><sec id="s2_3"><title>Radiotherapy</title><p>Patients were fixed in vacuumed pad in the supine position with both arms straight beside the body. The gross tumor volume (GTV) contained the primary tumor and metastatic lymph nodes identified by pre-treatment work-ups. The clinical tumor volume (CTV) consists of the primary tumor plus a 3-cm craniocaudal margin and a 1-cm circumferential margin, and metastatic lymph nodes plus a 0.5- to 1-cm expansion margin. For lower-thoracic ESCC, the paracardial, lesser gastric curvature and the left gastric artery nodes were included in CTV, while for cervical and upper-thoracic ESCC, the supraclavicular area was included. The planning target volume (PTV) was derived from expanding GTV and CTV with a 0.5cm margin in all directions, respectively. A total dose of 60Gy with a fraction dose 2.5Gy was delivered to PTV-GTV and 40Gy in 16 fractions to PTV-CTV using a linear accelerator with 6- to 10-MV photons. And at least 95% of PTV volume received 95% of the prescription dose. The dose constraints to the organs at risk were as follows: Dmax of PTV-GTV &#8804;63Gy, V20 of lungs &#8804; 30%, Dmean of lungs &#8804;13Gy, Dmax of spinal cord &#8804;45Gy, V30 of heart &#8804;30%, V30 of liver &#8804;20%, V5 of kidney &#8804; 10%. In the study, intensity-modulated radiation therapy (IMRT) technology was applied for treatment planning and delivery. In addition, image guidance with cone-beam CT (CBCT) was performed weekly to verify the tumor position and ensure the precision of radiotherapy.</p></sec><sec id="s2_4"><title>Chemotherapy</title><p>S-1 was administered at 40mg/m2 twice daily within half an hour after meals on days 1-14 and 22-35 during treatment. In the event of Grade 2 thrombocytopenia, anemia, hepatic or renal dysfunction, Grade 3 leukopenia/neutropenia, Grade 2 radiation esophagitis, pneumonitis and other Grade 2 non-hematological toxicities, the dosage of S-1 was reduced by 25%. If more severe toxicity occurred S-1 was suspended. However, if the adverse events degraded to Grade 0-1 within 1 week of drug withdrawal, the patient could retake S-1 at 75% of the original dose, otherwise, S-1 was terminated henceforward.</p></sec><sec id="s2_5"><title>Percutaneous endoscopic gastrostomy and nutritional intervention</title><p>One week before CCRT, eligible patients received percutaneous endoscopic gastrostomy. Gastrostomy tubes were placed using the &#8220;pull&#8221; method introduced by Ponsky et&#160;al (<xref rid="B20" ref-type="bibr">20</xref>). In this method, a thin string was inserted into the stomach through a needle in the abdominal wall, grabbed with endoscopic biopsy forceps and then taken out through the esophagus and mouth. Subsequently, the cord was fixed to the outer end of the gastrostomy tube and the tube was pulled from the mouth to the esophagus, stomach, and out through the abdominal wall. Proton pump inhibitors and antibiotics were routinely used for 3 days after PEG. Subsequently, patients need to follow a strict oral diet protocol: 1)all nutritional supplements were given <italic toggle="yes">via</italic> gastrostomy tube during and 2-3 months post-CCRT; 2) Only saline solution, purified water and S-1 were allowed to be taken orally before gastrostomy tube removal; 3) oral liquid diet could be recovered when endoscopy showed no ulcer or residual tumor, patient-generated subjective global assessment (PG-SGA) score&lt;4 points, weight loss less than 2% within 1 month and the nutrition-related indicators meeting standard levels (hemoglobin&#8805;100g/L, albumin&#8805;35g/L and prealbumin&#8805;20mg/mL); 4) It was recommended to retain the gastrostomy tube for 1-2 months after resuming oral liquid diet, and then removed the tube if there are no abnormalities (<xref rid="f1" ref-type="fig">
<bold>Figures&#160;1A</bold>
</xref>, <xref rid="f1" ref-type="fig">
<bold>1B</bold>
</xref>)</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>
<bold>(A)</bold> The study protocol for percutaneous endoscopic gastrostomy and endoscopy evaluation. <bold>(B)</bold> A 76-year-old, male patient was diagonsed with middle thoracic ESCC. Three months after the completion of CCRT, the endoscopy showed no ulcer or tumor residue and the gastrostomy tube was removed. <bold>(C)</bold> A 62-year-old, male patient was diagnosed with upper thoracic ESCC. The patient got complete remission at 2 months after the completion of CCRT, but esophageal ulcers were found in the endoscopic examination. And the gastrostomy tube placement was prolonged to 10 months post-CCRT till the mucosa was completely repaired. <italic toggle="yes">ESCC</italic>, esophagus carcinoma; <italic toggle="yes">CCRT</italic>, concurrent chemoradiotherapy; <italic toggle="yes">PG-SGA</italic>, patient-generated subjective global assessment; <italic toggle="yes">2m-post-CCRT</italic>, 2 months after CCRT; <italic toggle="yes">3m-post-CCRT</italic>, 3 months after CCRT; <italic toggle="yes">10m-post-CCRT</italic>, 10 months after CCRT; <italic toggle="yes">12m-post-CCRT</italic>, 12 months after CCRT.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-13-1138304-g001.jpg"/></fig><p>From the initiation of the treatment to 6 months post-CCRT, the PG-SGA score and nutrition-related indicators including weight, total protein, albumin, prealbumin, hemoglobin and lymphocyte were monitored and recorded regularly. Based on the PG-SGA score and the nutrition-related indicators, individualized and dynamic nutritional interventions were conducted on all subjects. All nutritional supplements were prescribed to meet final nutritional requirements (30-35 kcal/kg/d of energy, 30-40ml/kg/d of liquid and 1.2-1.5g/kg/d of protein).</p></sec><sec id="s2_6"><title>Toxicity</title><p>Radiation-induced esophagitis was evaluated weekly during treatment and four weeks after the completion of CCRT. Acute radiation pneumonitis was assessed from the initiation of treatment to 90 days after cessation of therapy. Other acute toxicities were recorded at baseline, weekly during CCRT and two weeks after the completion of therapy. All treatment-related toxicities were graded in terms of the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (version 4.0). Serious adverse events (SAE) must be reported to the institutional review board within 24h and dealt with properly.</p></sec><sec id="s2_7"><title>Response evaluation and follow-up</title><p>At six to eight weeks after the completion of CCRT, treatment response was evaluated based on clinical work-ups including barium video-esophagography, contrast-enhanced computed tomography (CT) of neck, chest and abdomen, contrast-enhanced chest magnetic resonance imaging (MRI), upper gastrointestinal endoscopy and biopsy (if necessary). Positron emission tomography/computed tomography (PET/CT) scans were encouraged. And the Response Evaluation Criteria in Solid Tumors (RECIST) was applied to classify tumor response as progressive disease (PD), stable disease (SD), partial response (PR) or complete response (CR). All patients were then followed every 3 months for the first 2 years, every 6 months for years 3-5 and yearly thereafter. Every follow-up included history, physical examination, blood routine, basic metabolic panel, contrast-enhanced CT of the neck, thorax and abdomen, contrast-enhanced chest MRI, endoscopy and biopsy (if necessary). Notably, endoscopy was routinely performed at each post-treatment follow-up in the study.</p></sec><sec id="s2_8"><title>Statistical analysis</title><p>Descriptive statistics were conducted for the analysis of baseline characteristics and treatment-related toxicities. The objective response rate (ORR) was defined as the rate of complete response and partial response. Overall survival (OS) was calculated from treatment start to the date of death from any cause or censored at the last follow-up. Progression-free survival (PFS) was calculated from treatment start to the date of locoregional failure or distant metastasis or death, whichever occurred first. Locoregional progression-free survival (LRPFS) was calculated from treatment start to the date of the diagnosis of a locoregional recurrence as the first event. Distant metastasis-free survival (DMFS) was calculated from the treatment start to the date of distant metastasis. All data analyses were conducted using SPSS version 22.0. The survival rates were estimated using the Kaplan-Meier method and differences in the survival curves were compared by the log-rank test. Statistical comparisons were performed by using unpaired t-tests. P&lt;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3_1"><title>Patient characteristics</title><p>From November 2017 and November 2019, a total of 75 patients were screened at our medical institution. Seventeen patients were excluded for declining protocol-specific treatment or lost to follow-up. The remaining 58 patients were included in the final analysis (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>). Overall, the median age of included patients was 63 years (range 49-83 years). Males comprised a majority of the cohort (75.9%), as did upper or middle thoracic tumors. Sixteen (27.6%) patients had stage IIB diseases and 35 (60.3%) patients had stage III diseases. Three patients with middle thoracic ESCC were classified as stage IVB for supraclavicular lymph node metastases. Detailed characteristics are presented in <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>.</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>The flow chart of patient enrollment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-13-1138304-g002.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Patient characteristics for the whole cohort (n=58).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="center" rowspan="1" colspan="1">No.</th><th valign="top" align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><th valign="top" colspan="3" align="left" rowspan="1">Age(years)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;median</td><td valign="top" colspan="2" align="center" rowspan="1">63</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;range</td><td valign="top" colspan="2" align="center" rowspan="1">49-83</td></tr><tr><th valign="top" colspan="3" align="left" rowspan="1">Sex</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;female</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">24.1%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Male</td><td valign="top" align="center" rowspan="1" colspan="1">44</td><td valign="top" align="center" rowspan="1" colspan="1">75.9%</td></tr><tr><th valign="top" colspan="3" align="left" rowspan="1">ECOG PS</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;0</td><td valign="top" align="center" rowspan="1" colspan="1">34</td><td valign="top" align="center" rowspan="1" colspan="1">58.6%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;1</td><td valign="top" align="center" rowspan="1" colspan="1">24</td><td valign="top" align="center" rowspan="1" colspan="1">41.4%</td></tr><tr><th valign="top" colspan="3" align="left" rowspan="1">Location of primary tumor</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;cervical esophagus</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">13.8%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;upper thoracic esophagus</td><td valign="top" align="center" rowspan="1" colspan="1">20</td><td valign="top" align="center" rowspan="1" colspan="1">34.5%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;middle thoracic esophagus</td><td valign="top" align="center" rowspan="1" colspan="1">22</td><td valign="top" align="center" rowspan="1" colspan="1">37.9%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;lower thoracic esophagus</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">10.4%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;synchronous multiple primary cancer</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">3.4%</td></tr><tr><th valign="top" colspan="3" align="left" rowspan="1">cT stage</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;T2</td><td valign="top" align="center" rowspan="1" colspan="1">17</td><td valign="top" align="center" rowspan="1" colspan="1">29.3%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;T3</td><td valign="top" align="center" rowspan="1" colspan="1">31</td><td valign="top" align="center" rowspan="1" colspan="1">53.5%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;T4</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1">17.2%</td></tr><tr><th valign="top" colspan="3" align="left" rowspan="1">cTNM Stage</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;IIB</td><td valign="top" align="center" rowspan="1" colspan="1">16</td><td valign="top" align="center" rowspan="1" colspan="1">27.6%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;III</td><td valign="top" align="center" rowspan="1" colspan="1">35</td><td valign="top" align="center" rowspan="1" colspan="1">60.3%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;IVA</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">6.9%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;IVB</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">5.2%</td></tr></tbody></table></table-wrap></sec><sec id="s3_2"><title>Treatment details and responses</title><p>Fifty-six patients completed radiotherapy as per protocol, while two patients only completed 19 of 24 fractions (47.5Gy) because of persistent Grade 3 esophagitis and Grade 3 leukopenia, respectively. Radiation therapy interruption occurred in six patients (10.4%). Seven patients discontinued concurrent chemotherapy due to gastrointestinal (n=4) and hematological toxicities (n=3). Chemotherapy dose reduction occurred in 12.1% of patients. Notably, all patients received PEG before treatment for nutritional intervention.</p><p>Six to eight weeks after the completion of CCRT, 35 (60.3%) patients were assessed as CR and 18 (31.0%) patients as PR. The ORR was 91.3%.</p></sec><sec id="s3_3"><title>Survival and failure patterns</title><p>The median follow-up duration was 24.4 (range 3.9-46.8) months and the estimated 2-year OS rate was 71.4% (95% confidence interval (CI), 59.4-83.4%, <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3A</bold>
</xref>). During the follow-up period, 12 patients (20.7%) had locoregional recurrence as the first failure. Distant metastases as the first failure occurred in 14 (24.1%) patients (lung, n=5; out-of-field nodal, n=5; abdomen, n=2; multiple organs metastases, n=2). Moreover, 5 (8.6%) patients had both locoregional recurrence and distant metastases as the first failure (<xref rid="f3" ref-type="fig">
<bold>Figure&#160;3E</bold>
</xref>). The estimated 2-year PFS rate was 44.2% (95%CI, 31.3-57.1%, <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3B</bold>
</xref>) and the median PFS was 16.4 (95%CI, 9.3-23.6) months. The estimated 2-year LRPFS rate and DMFS rate were 64.6% (95%CI, 51.7-77.5%, <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3C</bold>
</xref>) and 65.1% (95%CI, 52.4-77.8%, <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3D</bold>
</xref>), respectively. Patients with progressive disease received timely salvage therapy, with 12 patients receiving systemic chemotherapy alone, 9 patients receiving a combination of immunotherapy and chemotherapy, and 5 patients receiving re-radiation combined with chemotherapy.</p><fig position="float" id="f3" orientation="portrait"><label>Figure&#160;3</label><caption><p>
<bold>(A&#8211;D)</bold> Overall survival, progression-free survival, locoregional progression-free survival, and distant metastasis-free survival curves for all patients. The broken lines represent the upper and lower limits of the 95% CI of the survival curve, respectively. <bold>(E)</bold> Tumor swimmer plot for all patients. CR, PR, SD and PD were evaluated by the RECIST criteria based on CT, MRI, endoscopy and biopsy at six to eight weeks after the completion of CCRT. <italic toggle="yes">CCRT</italic>, concurrent chemoradiotherapy; <italic toggle="yes">RECIST</italic>, response evaluation criteria in solid tumors; <italic toggle="yes">CR</italic>, complete remission; <italic toggle="yes">PR</italic>, partial remission; <italic toggle="yes">SD</italic>, stable disease; <italic toggle="yes">PD</italic>, progressive disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-13-1138304-g003.jpg"/></fig></sec><sec id="s3_4"><title>Toxicity</title><p>All acute toxicities are reported in <xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>. The most frequent non-hematologic toxicity was esophagitis. 36 patients (62.1%) had grade 2 esophagitis and 5 patients (8.6%) developed grade&#8805;3 esophagitis. Radiation-induced esophagitis is mainly characterized by esophagus pain, and strong opioids were administered to 8 patients for pain relief. Only one patient occurred with esophago-mediastinal fistula and none presented with grade 3-4 pneumonitis in the study. The most common grade&#8805;3 hematological toxicity was lymphopenia (22/58, 37.9%), followed by leukopenia (2/58, 3.4%).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>Treatment-related adverse events (n=58).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" rowspan="2" align="left" colspan="1">Adverse event</th><th valign="top" colspan="4" align="center" rowspan="1">Grade, n (%)</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">1</th><th valign="top" align="center" rowspan="1" colspan="1">2</th><th valign="top" align="center" rowspan="1" colspan="1">3</th><th valign="top" align="center" rowspan="1" colspan="1">4</th></tr></thead><tbody><tr><th valign="top" colspan="5" align="left" rowspan="1">Hematological</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;anemia</td><td valign="top" align="center" rowspan="1" colspan="1">15(25.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">7(12.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;leukopenia</td><td valign="top" align="center" rowspan="1" colspan="1">23(39.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">13(22.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">2(3.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;lymphopenia</td><td valign="top" align="center" rowspan="1" colspan="1">5(8.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">30(51.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">22(37.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;neutropenia</td><td valign="top" align="center" rowspan="1" colspan="1">7(12.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">4(6.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;thrombocytopenia</td><td valign="top" align="center" rowspan="1" colspan="1">10(17.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">1(1.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><th valign="top" colspan="5" align="left" rowspan="1">Liver</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;hyperbilirubinemia</td><td valign="top" align="center" rowspan="1" colspan="1">9(15.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;increased liver enzyme</td><td valign="top" align="center" rowspan="1" colspan="1">18(31.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><th valign="top" colspan="5" align="left" rowspan="1">Gastrointestinal</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;esophagitis</td><td valign="top" align="center" rowspan="1" colspan="1">16(27.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">36(62.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">5(8.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;esophageal fistula</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1(1.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;nausea</td><td valign="top" align="center" rowspan="1" colspan="1">18(31.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">9(15.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">1(1.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;vomiting</td><td valign="top" align="center" rowspan="1" colspan="1">9(15.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">9(15.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">1(1.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;anorexia</td><td valign="top" align="center" rowspan="1" colspan="1">27(46.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">9(15.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">1(1.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;diarrhea</td><td valign="top" align="center" rowspan="1" colspan="1">6(10.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">6(10.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">2(3.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;constipation</td><td valign="top" align="center" rowspan="1" colspan="1">4(6.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><th valign="top" colspan="5" align="left" rowspan="1">Pulmonary</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;pneumonitis</td><td valign="top" align="center" rowspan="1" colspan="1">33(56.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">8(13.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;cough</td><td valign="top" align="center" rowspan="1" colspan="1">14(24.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">19(32.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;dyspnea</td><td valign="top" align="center" rowspan="1" colspan="1">1(1.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;chest pain</td><td valign="top" align="center" rowspan="1" colspan="1">2(3.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;hoarseness</td><td valign="top" align="center" rowspan="1" colspan="1">4(6.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><th valign="top" colspan="5" align="left" rowspan="1">General</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;dermatitis</td><td valign="top" align="center" rowspan="1" colspan="1">16(27.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">5(8.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">1(1.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;fatigue</td><td valign="top" align="center" rowspan="1" colspan="1">29(50.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">6(10.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap></sec><sec id="s3_5"><title>Longitudinal changes of nutritional status</title><p>The changes of nutrition-related indicators are presented in <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4</bold>
</xref>. As illustrated, the nutrition-related indicators including hemoglobin, total protein, albumin, prealbumin and lymphocyte significantly decreased in the early stage of treatment. However, with intensive nutrition intervention, the nutrition-related indicators presented a clear trend toward a gradual improvement and returned to initial levels within 3 to 6 months post-CCRT. Meanwhile, the body weight of patients remained stable throughout the treatment. 47 patients (81.0%) removed the gastrostomy feeding tube at the first or second follow-up, while 3 patients (5.2%) retained the tube for&#8805;12 months. The median duration of gastrostomy tube retention was 4.1 (range 2.9-12.5) months.</p><fig position="float" id="f4" orientation="portrait"><label>Figure&#160;4</label><caption><p>The changes longitudinal of nutrition-related indicators. <italic toggle="yes">mid-CCRT</italic>, 2 weeks after the start of CCRT; <italic toggle="yes">end-CCRT</italic>, the end of CCRT; <italic toggle="yes">3m-post-CCRT</italic>, 3 months after CCRT; <italic toggle="yes">6m-post-CCRT</italic>, 6 months after CCRT.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-13-1138304-g004.jpg"/></fig></sec><sec id="s3_6"><title>Endoscopy evaluation and follow-up</title><p>Notably, endoscopy was routinely performed at each post-treatment review in the study. Compared with imaging examination alone, endoscopy showed some obvious advantages: first, endoscopy could directly observe the changes in esophageal mucosa and help decide the time for extubation. As shown in <xref rid="f1" ref-type="fig">
<bold>Figure&#160;1C</bold>
</xref>, the patient got complete remission as assessed by imaging examination at two months after the completion of CCRT, but esophageal ulcers were found in endoscopic examination and no residual tumor was found in the pathological biopsy. In this case, the gastrostomy tube placement was prolonged until the mucosa was completely repaired; second, endoscopy contributed to the early detection of mucosal lesions. As presented in <xref rid="f5" ref-type="fig">
<bold>Figure&#160;5A</bold>
</xref>, the treatment response of the case was assessed as CR. At the third review after treatment, imaging examination showed no disease progression, but endoscopic examination revealed a small ulcerative lesion and pathological biopsy confirmed recurrence. Thus, the comprehensive examination method adopted in the study was more conducive to early detection of disease progression and timely subsequent treatment to prolong the overall survival time.</p><fig position="float" id="f5" orientation="portrait"><label>Figure&#160;5</label><caption><p>Disease evaluation by endoscopy, CT, T1-weighted, T2-weighted and diffusion-weighted sequences of MRI. <bold>(A)</bold> A 56-year-old, male patient was diagnosed with ESCC, which was located in the upper and middle thoracic esophagus. The treatment response of the case was assessed as CR after receiving CCRT. At 8 months after the completion of treatment, imaging examination showed no obvious abnormalities, but endoscopic examination revealed a small ulcerative lesion (red arrow) and pathological biopsy confirmed recurrence. <bold>(B)</bold> A 67-year-old, male patient was diagnosed with ESCC, which is located in the middle thoracic esophagus. The patient achieved CR after receiving CCRT and remained disease-free status in the 2-year follow-up period. <italic toggle="yes">ESCC</italic>, esophagus carcinoma; <italic toggle="yes">CCRT</italic>, concurrent chemoradiotherapy; <italic toggle="yes">CR</italic>, complete remission; <italic toggle="yes">3m-post-CCRT</italic>, 3 months after CCRT; <italic toggle="yes">8m-post-CCRT</italic>, 6 months after CCRT; <italic toggle="yes">24m-post-CCRT</italic>, 24 months after CCRT.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-13-1138304-g005.jpg"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>With regard to the combined efficacy of moderately hypo-fractionated radiotherapy, concurrent S-1 and PEG nutritional support, 35 of 58 patients (60.3%) got CR and the overall ORR was 91.3%. Meanwhile, the estimated 2-year OS rate and 2-year PFS rate were 71.4% and 44.2%, respectively. The gross tumor volume was reduced by 100% after the completion of CCRT in 60.3% of patients (35/58) with a pretreatment volume ranging from 21.9 to 203.3cm3. In addition, PEG nutritional support during CCRT was helpful to maintain the nutritional status of all subjects. Therefore, with the potent new CCRT regimens and nutritional management, promising tumor regression was achieved with moderated toxicities.</p><p>In clinical practice, CCRT has been broadly applied as the standard therapeutic strategy for LA-ESCC patients. But how to improve locoregional control and minimize treatment-related toxicities remains a tricky question. Recently, a phase I/II dose-escalation study conducted by Ma et&#160;al. indicated that a daily dose of &#8804;5Gy was safe in hypofractionated radiation for the treatment of ESCC (<xref rid="B21" ref-type="bibr">21</xref>). Meanwhile, compared to conventional radiation, moderately hypofractionated radiation could significantly decrease the risk of locoregional failure with a clear tendency toward additional survival benefits (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B21" ref-type="bibr">21</xref>). Therefore, moderately hypofractionated radiation with a fraction dose of 2.5Gy was adopted in the study. In the proposed chemotherapy regimen, we replaced the classical dual-drug regimen (capecitabine/fluorouracil&amp;platinum) with S-1, a single chemotherapeutic drug taken orally. Compared with continuous infusion of fluorouracil, S-1 provides a more convenient way of administration and a superior radiosensitizing effect (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B22" ref-type="bibr">22</xref>&#8211;<xref rid="B24" ref-type="bibr">24</xref>).</p><p>Our study achieved a promising treatment response by combing moderately hypofractionated radiation with a single chemotherapeutic agent. Assessing treatment response at six to eight weeks after the completion of CCRT, we found that 35 (60.3%) patients achieved CR and the ORR was 91.3%. In the majority of published clinical trials where patients received dual-drug regimen chemotherapy with concurrent radiotherapy, the reported ORR was approximately 75-90% (<xref rid="B25" ref-type="bibr">25</xref>&#8211;<xref rid="B27" ref-type="bibr">27</xref>). Thus, compared with the previous data, our study presented a satisfactory tumor treatment response. After close long-term follow-up, 12 patients (20.7%) were found to have the locoregional recurrence as the first failure by endoscopy examination. Distant metastases as the first failure occurred in fourteen (24.1%) cases. Another 5 (8.6%) patients presented both locoregional disease and distant metastases as the first failure. Compared with the data reported by RTOG 8501 and RTOG 9405 (locoregional failure rate was as high as 50% and 56%, respectively) (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B3" ref-type="bibr">3</xref>), the incidence of locoregional recurrence in the current study was relatively lower.</p><p>As reported by previous RTOG trials, severe acute esophageal toxicities (grade&#8805;3) occurred in 25-60% of ESCC patients who received chemoradiation (<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B4" ref-type="bibr">4</xref>). In our study, the incidence of grade 3 esophagitis and adverse gastrointestinal reactions was 8.6% and 5.1%, respectively. Only one patient developed esophago-mediastinal fistula and none presented with grade 3-4 pneumonitis. These results demonstrated that PEG nutritional support and oral diet restriction were helpful to reduce esophageal friction injury and promote repair, thereby reducing acute esophageal toxicities. Meanwhile, intensive nutritional interventions also exerted a positive effect in maintaining nutritional status, reducing adverse events and improving the immune function of patients with esophageal carcinoma. Overall, the new regimen recommended by our study showed a safe toxicity profile.</p><p>As is well-known, the incidence of malnutrition in esophageal carcinoma patients ranks first among all types of malignancies, reaching 67% to 85% (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). Relevant literature reported that malnutrition not only reduces the sensitivity of chemoradiotherapy but also increases treatment-related toxicities (<xref rid="B30" ref-type="bibr">30</xref>&#8211;<xref rid="B32" ref-type="bibr">32</xref>). As illustrated in <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3</bold>
</xref>, the nutrition-related indicators significantly decreased in the early stage of treatment. However, with active nutrition intervention, the nutrition-related indicators presented a clear trend toward a gradual improvement and returned to initial levels within 3 to 6 months post-CCRT. Meanwhile, the body weight of patients remained stable throughout the treatment. Furthermore, the radiation-induced esophagitis was significantly reduced by intensive PEG nutritional support and oral diet restriction. Therefore, nutritional management during chemoradiotherapy is helpful to normalize food intake and improve the nutritional status of ESCC patients.</p><p>Recently, a multicenter randomized phase 3 clinical trial conducted by Chen et&#160;al. evaluated the efficacy and safety of CCRT with S-1 <italic toggle="yes">vs</italic> radiotherapy alone in older ESCC patients (<xref rid="B17" ref-type="bibr">17</xref>). In the CCRT group, the median PFS intervals were 18.7 (95% CI, 12.1-25.2) months and the 2-year OS rate was 53.2%. Although the median PFS interval was slightly shorter in our study, our protocol achieved a significantly longer 2-year OS rate of 71.4%. The possible reasons for the difference included: 1) the age composition of our study is relatively young with a median age of 63 years versus 77 years in Chen&#8217;s study; 2) the hypofractionated radiation technique helped to improve the locoregional control; (<xref rid="f5" ref-type="fig">
<bold>Figure&#160;5B</bold>
</xref>). 3) endoscopy was conducted as the main examination method at each post-treatment review, which allowed early detection of recurrent disease and timely salvage treatment.</p><p>Several limitations of the current study should be taken into consideration. Firstly, this was a single-center prospective study with a relatively small sample size which may limit the generalization of our results. Secondly, although a total radiation dose of 50.4 Gy with a conventional fraction is recommended by the guidelines of National Comprehensive Cancer Network (NCCN), we delivered a total dose of 60Gy in the study. Considering ESCC as the major histological type of esophageal cancer in China, it is more susceptible to locoregional recurrence than esophagus adenocarcinoma (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). Recently, the randomized ARTDECO study approved that radiation escalation from 50.4Gy to 61.6Gy for esophageal tumors did not result in an improvement in local tumor control or survival and a dose of 50.4Gy could yield acceptable locoregional and survival outcomes (<xref rid="B5" ref-type="bibr">5</xref>). But in the ESCC subgroup, the 3-year local progression-free survival rate and LRPFS rate were both numerically better in the high dose group than in the standard group, although the difference was not statistically significant. Similar results were confirmed by a phase III multicenter randomized study of the radiation dose of 60Gy <italic toggle="yes">vs</italic> 50Gy in CCRT for inoperable ESCC (<xref rid="B35" ref-type="bibr">35</xref>). Meanwhile, the study reported that the difference in the incidence of &#8805;grade 3 all adverse events in the two groups was not statistically significant (P=0.5). Moreover, a total dose beyond 60Gy was also supported by some published literature as well as the guidelines of Chinese Society of Clinical Oncology (<xref rid="B36" ref-type="bibr">36</xref>&#8211;<xref rid="B39" ref-type="bibr">39</xref>). Thus, the optimal total radiation dose for ESCC remains controversial and the radiation dose adjustment remains to be a focus of future clinical studies.</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusions</title><p>Although several limitations exist, our study showed that the moderately hypo-fractionated radiotherapy combined with S-1 showed promising loco-regional disease control and survival benefit in inoperable LA-ESCC patients. Meanwhile, favorable nutritional status and low incidence of severe radiation-induced esophagitis were observed in subjects receiving PEG nutritional support. Moreover, endoscopy examination contributes to the early detection of recurrent esophageal lesions and timely salvage treatment. The efficacy and toxicity of the combined regimen deserved further evaluation.</p></sec><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>The studies involving human participants were reviewed and approved by Sun Yat-sen University Cancer Center. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. </p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>Study conception and design: RZ, GL, SG, BQ and HL. Literature review: RZ and BQ. Data acquisition: YW, QL, DW, NC, FL, JG, and WY. Statistical analysis: RZ, FL, DW, NC, and BQ. Data interpretation: RZ, GL, SG, BQ and HL. Manuscript preparation: RZ, GL, SG, and HL. Manuscript review: All authors. All authors contributed to the article and approved the submitted version.</p></sec></body><back><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s11"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2023.1138304/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fonc.2023.1138304/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Presentation_1.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minsky</surname><given-names>BD</given-names></name><name name-style="western"><surname>Pajak</surname><given-names>TF</given-names></name><name name-style="western"><surname>Ginsberg</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Pisansky</surname><given-names>TM</given-names></name><name name-style="western"><surname>Martenson</surname><given-names>J</given-names></name><name name-style="western"><surname>Komaki</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>INT 0123 (Radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy</article-title>. <source>J Clin Oncol</source> (<year>2002</year>) <volume>20</volume>(<issue>5</issue>):<page-range>1167&#8211;74</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.2002.20.5.1167</pub-id><pub-id pub-id-type="pmid">11870157</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaspar</surname><given-names>LE</given-names></name><name name-style="western"><surname>Winter</surname><given-names>K</given-names></name><name name-style="western"><surname>Kocha</surname><given-names>WI</given-names></name><name name-style="western"><surname>Coia</surname><given-names>LR</given-names></name><name name-style="western"><surname>Herskovic</surname><given-names>A</given-names></name><name name-style="western"><surname>Graham</surname><given-names>M</given-names></name></person-group>. <article-title>A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation therapy oncology group study 9207): final report</article-title>. <source>Cancer</source> (<year>2000</year>) <volume>88</volume>(<issue>5</issue>):<page-range>988&#8211;95</page-range>. doi:&#160;<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(sici)1097-0142(20000301)88:5&amp;#x0003c;988::aid-cncr7&amp;#x0003e;3.3.co;2-l</pub-id><pub-id pub-id-type="pmid">10699886</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>JS</given-names></name><name name-style="western"><surname>Guo</surname><given-names>MD</given-names></name><name name-style="western"><surname>Herskovic</surname><given-names>A</given-names></name><name name-style="western"><surname>Macdonald</surname><given-names>JS</given-names></name><name name-style="western"><surname>Martenson</surname><given-names>JA</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Al-Sarraf</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). radiation therapy oncology group</article-title>. <source>JAMA</source> (<year>1999</year>) <volume>281</volume>(<issue>17</issue>):<page-range>1623&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.281.17.1623</pub-id><pub-id pub-id-type="pmid">10235156</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minsky</surname><given-names>BD</given-names></name><name name-style="western"><surname>Neuberg</surname><given-names>D</given-names></name><name name-style="western"><surname>Kelsen</surname><given-names>DP</given-names></name><name name-style="western"><surname>Pisansky</surname><given-names>TM</given-names></name><name name-style="western"><surname>Ginsberg</surname><given-names>R</given-names></name><name name-style="western"><surname>Benson</surname><given-names>A</given-names></name></person-group>. <article-title>Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: A preliminary analysis of the phase II intergroup trial 0122</article-title>. <source>J Clin Oncol</source> (<year>1996</year>) <volume>14</volume>(<issue>1</issue>):<page-range>149&#8211;55</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.1996.14.1.149</pub-id><pub-id pub-id-type="pmid">8558190</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hulshof</surname><given-names>MCCM</given-names></name><name name-style="western"><surname>Geijsen</surname><given-names>ED</given-names></name><name name-style="western"><surname>Rozema</surname><given-names>T</given-names></name><name name-style="western"><surname>Oppedijk</surname><given-names>V</given-names></name><name name-style="western"><surname>Buijsen</surname><given-names>J</given-names></name><name name-style="western"><surname>Neelis</surname><given-names>KJ</given-names></name><etal/></person-group>. <article-title>Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study)</article-title>. <source>J Clin Oncol</source> (<year>2021</year>) <volume>39</volume>(<issue>25</issue>):<page-range>2816&#8211;24</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.20.03697</pub-id><pub-id pub-id-type="pmid">34101496</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>YP</given-names></name><name name-style="western"><surname>Ma</surname><given-names>JB</given-names></name><name name-style="western"><surname>Hu</surname><given-names>LK</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>EC</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name></person-group>. <article-title>Phase I/II study of hypofractioned radiation with three-dimensional conformal radiotherapy for clinical T3-4N0-1M0 stage esophageal carcinoma</article-title>. <source>Technol Cancer Res Treat</source> (<year>2011</year>) <volume>10</volume>(<issue>1</issue>):<fpage>25</fpage>&#8211;<lpage>30</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.7785/tcrt.2012.500176</pub-id><pub-id pub-id-type="pmid">21214285</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herskovic</surname><given-names>A</given-names></name><name name-style="western"><surname>Martz</surname><given-names>K</given-names></name><name name-style="western"><surname>al-Sarraf</surname><given-names>M</given-names></name><name name-style="western"><surname>Leichman</surname><given-names>L</given-names></name><name name-style="western"><surname>Brindle</surname><given-names>J</given-names></name><name name-style="western"><surname>Vaitkevicius</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus</article-title>. <source>N Engl J Med</source> (<year>1992</year>) <volume>326</volume>(<issue>24</issue>):<page-range>1593&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJM199206113262403</pub-id><pub-id pub-id-type="pmid">1584260</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: A randomized, multicenter, phase III clinical trial</article-title>. <source>J Clin Oncol</source> (<year>2019</year>) <volume>37</volume>(<issue>20</issue>):<page-range>1695&#8211;703</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.18.02</pub-id><pub-id pub-id-type="pmcid">PMC6638596</pub-id><pub-id pub-id-type="pmid">30920880</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>NB</given-names></name><name name-style="western"><surname>Li</surname><given-names>QW</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Guo</surname><given-names>SP</given-names></name><name name-style="western"><surname>Wu</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>ZJ</given-names></name><etal/></person-group>. <article-title>Docetaxel and nedaplatin twice a week with concurrent definitive radiotherapy in inoperable esophageal squamous cell carcinoma: A phase I trial (GASTO-1021)</article-title>. <source>Radiother Oncol</source> (<year>2021</year>) <volume>55</volume>:<page-range>105&#8211;12</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.radonc.2020.10.035</pub-id><pub-id pub-id-type="pmid">33144248</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>NW</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Leu</surname><given-names>YS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Chang</surname><given-names>YF</given-names></name></person-group>. <article-title>Prolonged radiation time and low nadir hemoglobin during postoperative concurrent chemoradiotherapy are both poor prognostic factors with synergistic effect on locally advanced head and neck cancer patients</article-title>. <source>Onco Targets Ther</source> (<year>2015</year>) <volume>8</volume>:<page-range>251&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2147/OTT.S70204</pub-id><pub-id pub-id-type="pmcid">PMC4315538</pub-id><pub-id pub-id-type="pmid">25670907</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>YH</given-names></name><name name-style="western"><surname>Lu</surname><given-names>HI</given-names></name><name name-style="western"><surname>Chien</surname><given-names>CY</given-names></name><name name-style="western"><surname>Lo</surname><given-names>CM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YM</given-names></name><name name-style="western"><surname>Chou</surname><given-names>SY</given-names></name><etal/></person-group>. <article-title>Efficacy of different chemotherapy regimens in patients with locally advanced synchronous esophageal and Head/Neck squamous cell carcinoma receiving curative concurrent chemoradiotherapy</article-title>. <source>J Clin Med</source> (<year>2020</year>) <volume>9</volume>(<issue>1</issue>):<elocation-id>197</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/jcm9010197</pub-id><pub-id pub-id-type="pmid">31936858</pub-id><pub-id pub-id-type="pmcid">PMC7020070</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCloskey</surname><given-names>SA</given-names></name><name name-style="western"><surname>Jaggernauth</surname><given-names>W</given-names></name><name name-style="western"><surname>Rigual</surname><given-names>NR</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>WL</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Popat</surname><given-names>SR</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck</article-title>. <source>Am J Clin Oncol</source> (<year>2009</year>) <volume>32</volume>(<issue>6</issue>):<page-range>587&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/COC.0b013e3181967dd0</pub-id><pub-id pub-id-type="pmid">19581794</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>an Groeningen</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Peters</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Schornagel</surname><given-names>JH</given-names></name><name name-style="western"><surname>Gall</surname><given-names>H</given-names></name><name name-style="western"><surname>Noordhuis</surname><given-names>P</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Phase I clinical and pharmacokinetic study of oral s-1 in patients with advanced solid tumors</article-title>. <source>J Clin Oncol</source> (<year>2000</year>) <volume>18</volume>(<issue>14</issue>):<page-range>2772&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.2000.18.14.2772</pub-id><pub-id pub-id-type="pmid">10894878</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirasaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Shimamato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ohshimo</surname><given-names>H</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name><name name-style="western"><surname>Yonekura</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators</article-title>. <source>Anticancer Drugs</source> (<year>1996</year>) <volume>7</volume>(<issue>5</issue>):<page-range>548&#8211;57</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/00001813-199607000-00010</pub-id><pub-id pub-id-type="pmid">8862723</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>G</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A phase I dose escalation study of s-1 with concurrent radiotherapy in elderly patients with esophageal cancer</article-title>. <source>J Thorac Dis</source> (<year>2016</year>) <volume>8</volume>(<issue>3</issue>):<page-range>451&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.21037/jtd.2016.02.70</pub-id><pub-id pub-id-type="pmcid">PMC4805812</pub-id><pub-id pub-id-type="pmid">27076940</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>A phase II study of s-1 with concurrent radiotherapy in elderly patients with esophageal cancer</article-title>. <source>Oncotarget</source> (<year>2017</year>) <volume>15 8</volume>(<issue>47</issue>):<page-range>83022&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.18632/oncotarget.20938</pub-id><pub-id pub-id-type="pmcid">PMC5669946</pub-id><pub-id pub-id-type="pmid">29137320</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Efficacy of concurrent chemoradiotherapy with s-1 vs radiotherapy alone for older patients with esophageal cancer: A multicenter randomized phase 3 clinical trial</article-title>. <source>JAMA Oncol</source> (<year>2021</year>) <volume>7</volume>(<issue>10</issue>):<page-range>1459&#8211;66</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jamaoncol.2021.2705</pub-id><pub-id pub-id-type="pmcid">PMC8343504</pub-id><pub-id pub-id-type="pmid">34351356</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>Y</given-names></name><name name-style="western"><surname>You</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Effect of whole-course nutrition management on patients with esophageal cancer undergoing concurrent chemoradiotherapy: A randomized control trial</article-title>. <source>Nutrition</source> (<year>2020</year>) <volume>69</volume>:<elocation-id>110558</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.nut.2019.110558</pub-id><pub-id pub-id-type="pmid">31526964</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sobin</surname><given-names>LCW</given-names></name><name name-style="western"><surname>Wittekind</surname><given-names>C</given-names></name></person-group>. <source>International union against cancer (UICC) TNM classification of malignant tumours</source>. <edition>6th</edition>. <publisher-loc>New York</publisher-loc>: <publisher-name>John Wiley and Sons</publisher-name> (<year>2002</year>).</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ponsky</surname><given-names>JL</given-names></name><name name-style="western"><surname>Gauderer</surname><given-names>MW</given-names></name><name name-style="western"><surname>Stellato</surname><given-names>TA</given-names></name></person-group>. <article-title>Percutaneous endoscopic gastrostomy. review of 150 cases</article-title>. <source>Arch Surg</source> (<year>1983</year>) <volume>118</volume>:<page-range>913&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1001/archsurg.1983.01390080021006</pub-id><pub-id pub-id-type="pmid">6409054</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>JB</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>EC</given-names></name><name name-style="western"><surname>Qin</surname><given-names>G</given-names></name><name name-style="western"><surname>Song</surname><given-names>YP</given-names></name><name name-style="western"><surname>Chen</surname><given-names>XM</given-names></name><etal/></person-group>. <article-title>Moderately hypofractionated conformal radiation treatment of thoracic esophageal carcinoma</article-title>. <source>Asian Pac J Cancer Prev</source> (<year>2012</year>) <volume>13</volume>(<issue>8</issue>):<page-range>4163&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.7314/apjcp.2012.13.8.4163</pub-id><pub-id pub-id-type="pmid">23098423</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukushima</surname><given-names>M</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Sakata</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>F</given-names></name><name name-style="western"><surname>Saito</surname><given-names>H</given-names></name><name name-style="western"><surname>Sakata</surname><given-names>Y</given-names></name></person-group>. <article-title>Gimeracil, a component of s-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo</article-title>. <source>Oncol Rep</source> (<year>2010</year>) <volume>24</volume>(<issue>5</issue>):<page-range>1307&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3892/or_00000987</pub-id><pub-id pub-id-type="pmid">20878125</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takagi</surname><given-names>M</given-names></name><name name-style="western"><surname>Sakata</surname><given-names>K</given-names></name><name name-style="western"><surname>Someya</surname><given-names>M</given-names></name><name name-style="western"><surname>Tauchi</surname><given-names>H</given-names></name><name name-style="western"><surname>Iijima</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Gimeracil sensitizes cells to radiation <italic toggle="yes">via</italic> inhibition of homologous recombination</article-title>. <source>Radiother Oncol</source> (<year>2010</year>) <volume>96</volume>(<issue>2</issue>):<page-range>259&#8211;66</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.radonc.2010.05.020</pub-id><pub-id pub-id-type="pmid">20584556</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Liao</surname><given-names>C</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name></person-group>. <article-title>S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: A meta-analysis</article-title>. <source>Med Oncol</source> (<year>2011</year>) <volume>28</volume>(<issue>4</issue>):<page-range>1004&#8211;11</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s12032-010-9594-0</pub-id><pub-id pub-id-type="pmid">20552300</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DE</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>JE</given-names></name><name name-style="western"><surname>Bae</surname><given-names>WK</given-names></name><name name-style="western"><surname>Nam</surname><given-names>TK</given-names></name><name name-style="western"><surname>Na</surname><given-names>KJ</given-names></name><etal/></person-group>. <article-title>A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer</article-title>. <source>Cancer Chemother Pharmacol</source> (<year>2012</year>) <volume>70</volume>(<issue>5</issue>):<page-range>683&#8211;90</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00280-012-1962-3</pub-id><pub-id pub-id-type="pmid">22932694</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>B</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>A phase II randomized controlled trial: Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with oesophageal squamous cell carcinoma</article-title>. <source>J Cancer</source> (<year>2017</year>) <volume>10 8</volume>(<issue>18</issue>):<page-range>3657&#8211;66</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.7150/jca.20053</pub-id><pub-id pub-id-type="pmcid">PMC5688918</pub-id><pub-id pub-id-type="pmid">29151952</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>QQ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Hu</surname><given-names>YH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>He</surname><given-names>ZY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>HX</given-names></name></person-group>. <article-title>Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma</article-title>. <source>Dis Esophagus</source> (<year>2010</year>) <volume>23</volume>(<issue>3</issue>):<page-range>253&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1442-2050.2009.01003</pub-id><pub-id pub-id-type="pmid">19732130</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bozzetti</surname><given-names>F</given-names></name><name name-style="western"><surname>Mariani</surname><given-names>L</given-names></name><name name-style="western"><surname>Lo Vullo</surname><given-names>S</given-names></name><name name-style="western"><surname>Amerio</surname><given-names>ML</given-names></name><name name-style="western"><surname>Biffi</surname><given-names>R</given-names></name><name name-style="western"><surname>Caccialanza</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>The nutritional risk in oncology: a study of 1,453 cancer outpatients</article-title>. <source>Support Care Cancer</source> (<year>2012</year>) <volume>20</volume>(<issue>8</issue>):<page-range>1919&#8211;28</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00520-012-1387-x</pub-id><pub-id pub-id-type="pmcid">PMC3390688</pub-id><pub-id pub-id-type="pmid">22314972</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#233;buterne</surname><given-names>X</given-names></name><name name-style="western"><surname>Lemari&#233;</surname><given-names>E</given-names></name><name name-style="western"><surname>Michallet</surname><given-names>M</given-names></name><name name-style="western"><surname>de Montreuil</surname><given-names>CB</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>SM</given-names></name><name name-style="western"><surname>Goldwasser</surname><given-names>F</given-names></name></person-group>. <article-title>Prevalence of malnutrition and current use of nutrition support in patients with cancer</article-title>. <source>JPEN J Parenter Enteral Nutr</source> (<year>2014</year>) <volume>38</volume>(<issue>2</issue>):<fpage>196</fpage>&#8211;<lpage>204</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1177/0148607113502674</pub-id><pub-id pub-id-type="pmid">24748626</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Correia</surname><given-names>MI</given-names></name><name name-style="western"><surname>Waitzberg</surname><given-names>DL</given-names></name></person-group>. <article-title>The impact of malnutrition on morbidity, mortality, length of hospital stay and costs evaluated through a multivariate model analysis</article-title>. <source>Clin Nutr</source> (<year>2003</year>) <volume>22</volume>:<page-range>235&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0261-5614(02)00215-7</pub-id><pub-id pub-id-type="pmid">12765661</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bozzetti</surname><given-names>F</given-names></name><name name-style="western"><surname>Arends</surname><given-names>J</given-names></name><name name-style="western"><surname>Lundholm</surname><given-names>K</given-names></name><name name-style="western"><surname>Micklewright</surname><given-names>A</given-names></name><name name-style="western"><surname>Zurcher</surname><given-names>G</given-names></name><name name-style="western"><surname>Muscaritoli</surname><given-names>M</given-names></name></person-group>. <article-title>ESPEN guidelines on parenteral nutrition: Non-surgical oncology</article-title>. <source>Clin Nutr</source> (<year>2009</year>) <volume>28</volume>(<issue>4</issue>):<page-range>445&#8211;54</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.clnu.2009.04.011</pub-id><pub-id pub-id-type="pmid">19477052</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>CS</given-names></name><name name-style="western"><surname>Read</surname><given-names>JA</given-names></name><name name-style="western"><surname>Phan</surname><given-names>VH</given-names></name><name name-style="western"><surname>Beale</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Peat</surname><given-names>JK</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>SJ</given-names></name></person-group>. <article-title>The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: A prospective cohort study</article-title>. <source>Support Care Cancer</source> (<year>2015</year>) <volume>23</volume>(<issue>2</issue>):<page-range>385&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00520-014-2385-y</pub-id><pub-id pub-id-type="pmid">25112562</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siewert</surname><given-names>JR</given-names></name><name name-style="western"><surname>Ott</surname><given-names>K</given-names></name></person-group>. <article-title>Are squamous and adenocarcinomas of the esophagus the same disease</article-title>? <source>Semin Radiat Oncol</source> (<year>2007</year>) <volume>17</volume>:<fpage>38</fpage>&#8211;<lpage>44</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.semradonc.2006.09.007</pub-id><pub-id pub-id-type="pmid">17185196</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siewert</surname><given-names>JR</given-names></name><name name-style="western"><surname>Stein</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Feith</surname><given-names>M</given-names></name><name name-style="western"><surname>Bruecher</surname><given-names>BL</given-names></name><name name-style="western"><surname>Bartels</surname><given-names>H</given-names></name><name name-style="western"><surname>Fink</surname><given-names>U</given-names></name></person-group>. <article-title>Histologic tumor type is an independent prognostic parameter in esophageal cancer: Lessons from more than 1,000 consecutive resections at a single center in the Western world</article-title>. <source>Ann Surg</source> (<year>2001</year>) <volume>234</volume>(<issue>3</issue>):<page-range>360&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/00000658-200109000-00010</pub-id><pub-id pub-id-type="pmcid">PMC1422027</pub-id><pub-id pub-id-type="pmid">11524589</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dong</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>A phase III multicenter randomized clinical trial of 60 gy versus 50 gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma</article-title>. <source>Clin Cancer Res</source> (<year>2022</year>) <volume>28</volume>(<issue>9</issue>):<page-range>1792&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-3843</pub-id><pub-id pub-id-type="pmid">35190815</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name><name name-style="western"><surname>Li</surname><given-names>CC</given-names></name><name name-style="western"><surname>Chien</surname><given-names>CR</given-names></name></person-group>. <article-title>Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? a population based propensity-score matched analysis</article-title>. <source>Radiother Oncol</source> (<year>2016</year>) <volume>120</volume>(<issue>1</issue>):<page-range>136&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.radonc.2016.04.042</pub-id><pub-id pub-id-type="pmid">27207358</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>CL</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>HC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>WC</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JH</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>HL</given-names></name><name name-style="western"><surname>Chow</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma</article-title>. <source>Radiother Oncol</source> (<year>2017</year>) <volume>125</volume>(<issue>1</issue>):<page-range>73&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.radonc.2017.08.025</pub-id><pub-id pub-id-type="pmid">28923576</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>HS</given-names></name><name name-style="western"><surname>Huang</surname><given-names>HC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>LX</given-names></name></person-group>. <article-title>Effect of modern high-dose versus standard-dose radiation in definitive concurrent chemo-radiotherapy on outcome of esophageal squamous cell cancer: a meta-analysis</article-title>. <source>Radiat Oncol</source> (<year>2019</year>) <volume>14</volume>(<issue>1</issue>):<fpage>178</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13014-019-1386-x</pub-id><pub-id pub-id-type="pmid">31623639</pub-id><pub-id pub-id-type="pmcid">PMC6798457</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Chinese Society of Esophageal Cancer</collab><collab>Chinese Anti-Cancer Association</collab></person-group>. <source>Clinical practice guidelines for the diagnosis and treatment of esophageal cancer</source>. <publisher-name>Peking Union Medical College Press</publisher-name> (<year>2011</year>).</mixed-citation></ref></ref-list></back></article></pmc-articleset>